Natural Alternatives International Inc key statistics and ratios
In fiscal 2026, Natural Alternatives International Inc had return on equity of -35.0% and a net margin of -14.5%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2011Jun 2011 | 2012Jun 2012 | 2013Jun 2013 | 2014Jun 2014 | 2015Jun 2015 | 2016Jun 2016 | 2017Jun 2017 | 2018Jun 2018 | 2019Jun 2019 | 2020Jun 2020 | 2021Jun 2021 | 2022Jun 2022 | 2023Jun 2023 | 2024Jun 2024 | 2025Jun 2025 | 2026Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net margin | 9.1% | 5.7% | 2.5% | 2.7% | 4.2% | 8.4% | 5.9% | 3.8% | 4.7% | −1.4% | 6.0% | 6.3% | 1.6% | −6.3% | −10.5% | −14.5% |
| Return on equity | 14.3% | 11.0% | 3.9% | 4.8% | 7.8% | 19.6% | 12.6% | 7.8% | 9.1% | −2.2% | 14.2% | 12.7% | 2.8% | −8.4% | −18.0% | −35.0% |
| Return on assets | 12.4% | 9.4% | 3.3% | 4.0% | 6.3% | 14.9% | 9.9% | 6.4% | 6.6% | −1.4% | 9.0% | 8.0% | 1.8% | −4.9% | −8.6% | −14.9% |
| Effective tax rate | — | 33.4% | 25.0% | 25.3% | 22.3% | 29.7% | 28.4% | 52.4% | 17.8% | — | 11.2% | 21.6% | 29.1% | — | — | — |
| R&D as % of revenue | 1.8% | 1.5% | 1.9% | 1.4% | 1.4% | 1.0% | 1.3% | 1.1% | 1.3% | 1.5% | 1.1% | 1.5% | 1.4% | 1.7% | 1.4% | 1.6% |
| SG&A as % of revenue | 14.9% | 12.7% | 15.9% | 13.5% | 12.8% | 11.4% | 13.5% | 12.7% | 12.7% | 14.4% | — | — | — | — | — | — |
| Quarter | 2025 Q1Sept 2024 | 2025 Q2Dec 2024 | 2025 Q3Mar 2025 | 2025 Q4Jun 2025 | 2026 Q1Sept 2025 | 2026 Q2Dec 2025 | 2026 Q3Mar 2026 | 2026 Q4Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Net margin | −6.0% | −6.4% | −7.6% | −21.3% | −0.8% | −7.3% | −12.1% | −39.2% |
| SG&A as % of revenue | 12.4% | 13.1% | 13.6% | — | 10.9% | 12.5% | 12.4% | — |
Financial health
- Short-term assets cover short-term liabilities $65m of assets due within a year against $38m of liabilities due within a year.
- Short-term assets cover long-term liabilities $65m short-term assets against $39m of longer-dated liabilities.
- More cash than debt $7m of cash against $10m of debt.
- Debt below 40% of shareholders' equity Debt is 20% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 11% to 20% over five years.
- A year's operating cash flow covers at least 20% of debt −$9m of operating cash flow against $10m of debt.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Moat
Weak moat
How hard Natural Alternatives International's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 5 / 20
Cash operating profit has been a median 5.4% of total assets over 9 years.
- Pricing power 5 / 20
Gross margin has been a median 16.5%, moving by 5.5 percentage points (standard deviation) across 10 years.
- Durability 0 / 20
Operating margin has been a median 3.7%; its worst year was -13.2%.
- Cash conversion 4 / 20
Free cash flow was positive in 4 of 10 years, at a median -1.7% of revenue.
- Discipline 19 / 20
The diluted share count fell 5.5% over five years; stock-based pay has been a median 0.8% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (32 before it).
Compare with peers
- Zevra Therapeutics, Inc. statistics
- Heron Therapeutics, Inc. statistics
- Niagen Bioscience, Inc. statistics
- Amarin Corp plc\uk statistics
- Cronos Group Inc. statistics
Head to head: NAII vs ZVRAHRTX vs NAIINAGE vs NAII
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies